On a per-share basis, the
The results topped
The biotech company that develops treatments targeting cancer and autoimmune diseases posted revenue of
For the year, the company reported that its loss narrowed to
In the final minutes of trading on Thursday, the company's shares hit
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a
Automated Insights, source